Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.51 |
| ▸ | AKT2 | P31751 | 5/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316851 | 0.79 | PDE4B (0.49) | AKT1AKT2PDE4BAKT3MEN1 | |
| SCHEMBL540893 | 0.79 | MAPK1 (0.59) | AKT1AKT2PDE4BMEN1KMT2A | |
| SCHEMBL2176676 | 0.79 | AKT1 (0.82) | AKT1AKT2AKT3 | |
| SCHEMBL30931249 | 0.79 | AKT1 (0.42) | AKT1AKT2PDE4BAKT3MEN1 | |
| SCHEMBL10051902 | 0.79 | AKT1 (0.65) | AKT1AKT2PDE4BAKT3MEN1 | |
| SCHEMBL804897 | 0.78 | ALDH1A1 (0.60) | AKT1AKT2PDE4BAKT3MEN1 | |
| SCHEMBL8805096 | 0.78 | ALDH1A1 (0.64) | AKT1AKT2PDE4BAKT3HCAR1 | |
| SCHEMBL21681303 | 0.77 | AKT1 (0.43) | AKT1AKT2PDE4BAKT3MEN1 | |
| SCHEMBL13916708 | 0.77 | ALDH1A1 (0.58) | AKT1AKT2PDE4BAKT3MEN1 | |
| SCHEMBL13314063 | 0.77 | AKT1 (0.52) | AKT1AKT2PDE4BAKT3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098220-B2 | Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-08-29 | — | — | US | disclosed |
| EP-1558612-B1 | IMIDAZOPYRIDINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-08-23 | — | — | EP | disclosed |
| US-20060069117-A1 | Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069117-A1 | Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same | PRKAA1, PRKAB1, PRKAB2 | AKT1 474/4885AKT2 558/4885PDE4B 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.